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SCLC- Small cell lung cancer 
ESMO- European Society of Medical Oncology 
PCI- Prophylactic cranial irradiation 
LD-SCLC- Limited stage small cell lung cancer 
RCT- Randomized controlled trial 
ED-SCLC- Extensive stage small cell lung cancer 
PS- Performance status 






We conducted a systematic review and meta-analysis of survival following treatment recommended 
by the European Society of Medical Oncology for SCLC in order to determine a benchmark for novel 
therapies to be compared with.   
Materials and Methods 
Randomized controlled trials and observational studies reporting overall survival following 
chemotherapy for SCLC were included. We calculated survival at 30 and 90-days along with 1-year, 
2-year and median.  
Results 
We identified 160 for inclusion. There were minimal 30-day deaths. Survival was 99% (95%CI 98.0-
99.0%, I233.9%, n=77) and 90% (95%CI 89.0-92.0%, I279.5%, n=73) at 90 days for limited (LD-SCLC) 
and extensive stage (ED-SCLC) respectively.   
The median survival for LD-SCLC was 18.1 months (95%CI 17.0-19.1%, I277.3%, n=110) and early 
thoracic radiotherapy (thoracic radiotherapy 18.4 months (95%CI 17.3-19.5, I278.4%, n=100)) vs no 
radiotherapy 11.7 months (95%CI 9.1-14.3, n=10), prophylactic cranial irradiation (PCI 19.7 months 
vs No PCI 13.0 months (95%CI 18.5-21.0, I275.7%, n=78 and 95%CI 10.5-16.6, I281.1%, n=15 
respectively)) and better performance status (PS0-1 22.5 months vs PS0-4 15.3 months (95%CI 18.7-
26.1, I272.4%, n=11 and 95%CI 11.5-19.1 I277.9%, n=13)) augmented this. For ED-SCLC the median 
survival was 9.6 months (95%CI 8.9-10.3%, I295.2%, n=103) and this improved when 
irinotecan+cisplatin was used, however studies that used this combination were mostly conducted in 
Asian populations where survival was better. Survival was not improved with the addition of thoracic 
radiotherapy or PCI.  
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Survival for both stages of cancer was better in modern studies and Asian cohorts. It was poorer for 
studies administering carboplatin+etoposide but this regimen was used in studies that had fewer 
patient selection criteria. 
Conclusion 
Early thoracic radiotherapy and PCI should be offered to people with LD-SCLC in accordance with 
guideline recommendations. The benefit of the aforementioned therapies to treat ED-SCLC and the 













The European Society of Medical Oncology (ESMO) recommend 4-6 cycles of cisplatin or carboplatin 
doublet chemotherapy as first-line treatment for all stages of SCLC.(1) Thoracic radiotherapy can be 
given concurrently, in fitter individuals with limited stage (LD-SCLC), or sequentially to people who 
have responded to initial chemotherapy. Prophylactic cranial irradiation (PCI) is generally reserved 
for people who have responded to chemotherapy. These treatments have remained unchanged for 
30 years but novel therapies are emerging. Immunotherapies such as atezolizumab (IMPOWER-133 
trial) and durvalumab (CASPIAN), in combination with chemotherapy, have shown increases in the 
median survival of approximately 2 and 3 months respectively when compared to chemotherapy 
alone.(2, 3) Both these treatments have been given approval for use in extensive stage SCLC (ED-
SCLC) by the US Food and Drug Administration. However, these new treatments are expensive and 
the U.K. list price for one vial of atezolizumab is approximately £3,800.(4) Hence, in order to assess 
whether these novel treatments are economically viable a comprehensive survival assessment of the 
existing therapies is needed. This will ensure that the claimed survival advantages of immunotherapy 
are accurate.  
Similarly, in order to maximise the efficacy of current treatments patients must be selected 
appropriately. Deaths occurring early after chemotherapy (within 30-days) are a measure of poor 
selection, but the evidence base for this in SCLC is limited.(5) Hence, the objectives of this study are 
to examine early and late survival by ESMO recommended treatments for SCLC in order to increase 
this evidence base and inform the appraisal process of novel treatments.  
Methods 
Search strategy 
We searched EMBASE, MEDLINE and electronic search engines for English language randomized 
controlled trials (RCTs) or observational cohort studies which reported overall survival following 
6 
 
receipt of cisplatin or carboplatin in combination with etoposide, irinotecan or topotecan for SCLC. 
The search strategy can be found in Supplement 1. Our search was conducted on 7th June 2016. After 
the initial search we examined the archives of the European Society of Medical Oncology, American 
Society of Clinical Oncology and the International Association for the Study of Lung Cancer for 
conference abstracts. We searched the references of included manuscripts. The search was 
completed on the 22nd November 2017. 
Inclusion Criteria 
The inclusion criteria are presented in Supplement 2 and were applied based on the study protocol 
published in the manuscript. We examined overall survival in treatment naïve individuals with SCLC 
who received platinum based chemotherapy in-keeping with ESMO guidelines.(1) Studies were 
excluded if “up front” prophylactic growth colony stimulating-factor or antibiotics were given before 
the first chemotherapy cycle as these are not routinely recommended in SCLC in the U.K.(6) If a 
study protocol was changed throughout its duration and this was not compatible with our inclusion 
criteria it was excluded. Abstract only publications were included. Manuscripts with duplicate study 
populations were used once, with the most up to date publication being included. Two reviewers 
(GJ, TM) applied the inclusion criteria, if there was disagreement a third was consulted (DRB or RBH) 
and a consensus was reached.  
Data extraction  
Three reviewers extracted data (GJ, KE, TM) consisting of trial design, participant characteristics, 
treatment schedule, survival (30-day, 90-day, 1-year, 2-year and median survival), cause of 30-day 
death and quality score. We used graph digitalizer software, Digitizelt V2.2, (Braunschweig, 
Germany) to extract survival data from Kaplan Meier plots if survival data was not within the text.(7-
9) Extracted values were crosschecked for accuracy. Our quality score combined the Cochrane risk of 
bias and Newcastle-Ottawa scoring methods (found in Supplement 3) to assess survival reporting 




All analyses were carried out using STATA V15 (TX, USA). We derived pooled survival estimates from 
individual treatment arms. For example, a study with two treatment regimens meeting our inclusion 
criteria would have two survival outcomes in our meta-analysis. We calculated a pooled survival 
estimate at: 30-days, 90-days, 1-year and 2-years using a random effects model allowing for 
Freeman-Tukey arcsine transformation to stabilize variances between studies.(10) The median 
survival estimate was produced from a random effects inverse-variance method (DerSimonian 
Laird).(11) Heterogeneity was quantified using the I2 statistic.(12) In studies where the median 
survival was presented without 95% confidence intervals (CI), we used a method by R.P Jones et al to 
estimate variance and 95%CIs.(13) We conducted a sensitivity analysis without these estimated 
values. 
Combined stage, LS-SCLC and ED-SCLC pooled survival estimates (with 95%CIs) were presented 
separately. Estimates were stratified by study factors and interventions. Studies were grouped by 
quality score; (poor (0-9), moderate (10-14), good (15-19) and very good (20-27)). Study design was 
classed as RCT or cohort. The study year and median participant age were divided into 10-year 
groups. The study region was the continent where it was conducted and broadly represents the 
ethnicity of the cohort. Performance status (PS) was derived from inclusion criteria and divided into 
0-1 to 0-4. Mixed/alternating chemotherapy regimens were grouped into: platinum+etoposide 
(cisplatin/carboplatin+etoposide) and platinum+etoposide/irinotecan 
(cisplatin/carboplatin+etoposide/irinotecan). Thoracic radiotherapy, if given, was grouped according 





We identified 10,487 titles and after screening 130 remained. Another 30 studies were identified 
from references of included manuscripts giving a total of 160 studies. Figure 1 is a flowchart of this 
process.  
Summary of studies 
In total, we examined survival data from 22,528 people. Supplement 4 summarises the included 
manuscripts, 11 of which were abstracts.(14-174) The majority of manuscripts were observational 
cohort studies (100 (62.5%)) and the remaining were randomized/non-randomized controlled trials 
(60 (37.5%). The earliest commenced in 1981, however, most were from 2000-2009 (67(41.9%)). 
Many studies were from Asia (60 (37.5%)) followed by Europe (45 (28.1 %)) and North America (36 
(22.5%)). The average, median participant age was 63 years (SD 5.3 years) and most were male 
(median proportion 78.9%). Studies mainly consisted of people with PS 0-2 (107 (66.9%)) and 31 
(19.4%) had minimum life expectancy criterion ranging from >8 weeks to >6 months. Other inclusion 
pre-requisites were adequate bone marrow, hepatic and renal function. Common exclusion criteria 
were pleural/pericardial effusions, cardiovascular disease and symptomatic brain metastases. 
The median quality score for cohort studies was 18.5/27 (IQR 15.5-20.5, range 7.5  to 24 (34, 145)) 
and 18.5/30 (IQR 17.25-19.75, range 10 to 19 (112, 148)) for RCTs. The causes for poorer quality 
were lack of reporting of early survival and cause of early death.  
Thirty day survival 
The 30-day survival for LD-SCLC studies was 100% (95% CI 100%, I2 0%, n=76) and for ED-SCLC it was 
96% (95% CI 95-97%, I2 67.3%, n=71). These varied minimally by study factors and are reported in 
Supplement 5.  We identified 31 studies where 75 people died within 30 days of chemotherapy and 
the cause of death was published (summarized in Supplements 6 & 7.) The majority of deaths were 
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attributed to neutropenic sepsis (n=27 (36.0%)), disease progression (n=11 (14.7%)) and 
cardiovascular, gastrointestinal and others (n=8 (10.7%) in each).  
Ninety day survival 
Table 1 demonstrates survival at 90 days stratified by study factors. Survival was 99% (95%CI 98-
99%, I233.9%, n=77) for LD-SCLC and varied minimally by study factors (forest plot Supplement 8).   
Survival was shorter in ED-SCLC (90% (95%CI 89-92%, I279.5%, n=73, forest plot Supplement 9). 
Survival improved in recent studies (2010-2015 96% (95%CI 89-99%, I281.6%, n=7)) and in Asian 
cohorts (97% (95%CI 95-98%, I242.8%, n=26)). Carboplatin+etoposide and cisplatin+topotecan had 
the poorest 90-day survival (88% (95%CI 83-92%, I277.3%, n=14) and 86% (95%CI 83-89%, I227.9%, 
n=35) respectively). Worse PS heralded lower 90-day survival (PS 0-4 87% (95%CI 74-96%, I292.7%, 
n=9)).   
Late survival 
We report late survival at 1-year (demonstrated in Table 2) and this varied considerably by stage.  
The 1-year survival for LD-SCLC was 73% (95%CI 70-75%, I274.0%, n=91, forest plot Supplement 10). 
This was better with Asian cohorts (79% (95%CI 75-82%, I260.9%, n=37)), receipt of 
irinotecan+etoposide (77% (95%CI 66-86%, I262.6%, n=7), young age (74% (95%CI 69-79, I261.7%, 
n=20)), early thoracic radiotherapy (77% (95%CI 73-80%, I268.0%, n=40) and PCI (75% (95%CI 72-
77%, I274.1%, n=69)). 
One-year survival for ED-SCLC was 38% (95%CI 35-40%, I274.9%, n=80, forest plot Supplement 11). 
This has improved with time (2010-2015 55% (95%CI 43-68%, I283.9%, n=7) vs 1980-1989 28% 
(95%CI 24-33%, I245.4%, n=15)). In addition, Asian cohorts (47% (95%CI 42-52, I272.9%, n=31)) and 
irinotecan+cisplatin (49% (95%CI 43-54%, I270.6%, n=15)) had better survival. Survival was not 
significantly different with age, PS or with the addition of thoracic radiotherapy and PCI. 
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The 2-year survival for LD-SCLC was 41% (95%CI 38-44%, I278.9%, n=85) and for ED-SCLC it was 9% 
(95%CI 7-10%, I267.5%, n=66). On the whole, there was significant variation in survival by the same 
study factors as those at 1-year. Hence, we have not presented these results in full. The table of 
results can be found in Supplement 12. 
Median survival 
The results of median survival are shown in Table 3. For LD-SCLC survival was 18.0 months (95%CI 
17.0-19.1, I277.3%, n=110 (forest plot Supplement 13)). This was longer with modern studies, Asian 
cohorts, better PS, young age, receipt of thoracic radiotherapy and PCI.  
For ED-SCLC median survival was 9.6 months (95%CI 8.9-10.3, I295.2%, n=103 (forest plot 
Supplement 14)). This was better for studies that gave irinotecan+etoposide, had Asian cohorts and 
included people with good PS. 
The aforementioned results showed significant heterogeneity and this was not reduced by the 
sensitivity analysis (studies with estimated 95%CIs removed) however, the conclusions remained the 
same.   
Discussion 
Main Findings 
There were few deaths within the 30 days of the first chemotherapy dose and these were 
predominantly due to neutropenic sepsis. Early survival was similar across all ages but this changed 
at 1-year for LD-SCLC, where the elderly were less likely to survive, most likely a result of attrition 
bias. Long term survival varied considerably by stage and was better in Asian cohorts and recent 
studies that included people with good PS. Thoracic radiotherapy and PCI augmented median 




To our knowledge, this is the largest systematic review conducted in SCLC. Quantifying early and late 
survival permits a better understanding of the early mortality risks of treatment vs the long-term 
survival gains, allowing better informed treatment choices and patient selection. The large number 
of included studies means our results are less prone to publication bias unlike other, smaller, 
systematic reviews.(175-177)  
Limitations 
In this study some factors, such as PCI and radiotherapy, do not consist of all the individuals who 
received these treatments as we categorised this variable from the study protocol. This grouping 
method was needed as there was significant heterogeneity in study design and reporting. However, 
our results are consistent with other literature. Our results do not fully represent “real world 
survival” as many patients in clinical practice do not meet trial inclusion criteria. However, we have 
included observational studies that have far less selection criteria than RCTs.  
Comparisons with other research 
Early survival 
The evidence base for early mortality and its causes following chemotherapy is limited. The 
proportion of treatment related deaths, defined as death related to and within 4 weeks of 
completion of chemotherapy, was found to be 2.95% in a systematic review of phase III SCLC 
trials.(178) Neutropenic sepsis was found to be the leading cause of these.  Conversely, 
observational research from England found that 30-day mortality for palliative and curative 
chemotherapy for SCLC was 12% and 4% respectively.(5) Our findings lie between these two studies 
as we have included clinical trials and observational studies.   
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Chemotherapy and cohort ethnicity 
Irinotecan+cisplatin tended to have better survival in comparison to cisplatin/carboplatin+etoposide 
and there are several explanations for this. First, carboplatin+etoposide regimens were more 
commonly used in studies that recruited patients with worse PS and more comorbidities, biasing 
carboplatin to poorer outcomes. Indeed, when the efficacy of cisplatin and carboplatin were 
compared in a systematic review of individual patient data there was no difference between the two 
(median overall survival 9.6 months and 9.4 months for cisplatin and carboplatin respectively). (179) 
Second, the majority of irinotecan containing studies have been conducted in Asia where it has more 
favourable outcomes.(175) However, outside of Asia there is limited evidence for its superiority over 
etoposide.(180) Indeed, a systematic review that included many of the same Asian, irinotecan 
studies as ours concluded that irinotecan augmented survival by 1-2 months compared to 
platinum+etoposide.(175) Contrastingly, a study in Caucasians found no differences in survival 
between etoposide and irinotecan containing chemotherapy.(180) The variation of irinotecan 
metabolism between ethnic groups is well documented and approximately 10% of Caucasians have a 
variant form of the UDP-glucuronosyltransferase 1 polypeptide A1 enzyme. This variant enzyme 
leads to poorer metabolism and subsequently irinotecan toxicity.(181) (182) 
The prevalence of SCLC amongst never-smokers is greatest in Asia and the augmented survival of 
Asian cohorts is likely a reflection of different SCLC aetiological exposures.(183) Indeed, evidence 
suggests that never-smokers with SCLC have better survival than ever-smokers.(184, 185) This 
observation is most pronounced in Asian females who have greater exposure to indoor air pollution 
from cooking oils rather than tobacco.(186) Similarly, genetic analysis of SCLC histological samples 
from never-smokers have shown a greater burden of oncogene driver mutations (such as EGFR) than 
in ever-smokers raising the concept of SCLC in never smokers being a distinct disease.(185) Other 




We found survival was shorter in older studies. Schabath et al drew similar conclusions when they 
compared the survival of two cohorts of people with SCLC treated at a single centre between 1986-
1999 and 2000-2008.(187) The median overall survival was significantly better in the 2000-2008 
cohort (11.3 months (95% CI 10.5-12.7)) in comparison to the 1986-1999 group (15.2 months (95%CI 
13.6-16.6)). This increase was attributed to greater use of multi-modality therapy rather than 
chemotherapy alone and less use of cyclophosphamide, doxorubicin and vincristine combination 
treatment.  In addition, the better selection of patients and improved healthcare practices e.g. 
infection control awareness, also explain our results. (25, 28, 41) (46, 142, 166, 167) (188). Lastly, 
improved methods for early detection and staging have caused a modest stage migration over time. 
This migration towards earlier stage subsequently improves overall survival, the so-called Will 
Rogers phenomenon. Indeed, the aforementioned study had greater proportions of LD-SCLC during 
2000-2008 (50.3%) in comparison to 1986-1999 (40.0%). 
Thoracic radiotherapy 
In-keeping with treatment recommendations, early radiotherapy in LD-SCLC augmented survival. A 
seminal meta-analysis of 7 RCTs demonstrated improvement in 2 and 3 year survival with thoracic 
radiotherapy if given within 9 weeks of chemotherapy.(189) Other meta-analyses have found that 
early radiotherapy increases survival but causes more side effects e.g. severe oesophagitis.(190, 191)  
Prophylactic cranial irradiation 
Our findings align with a systematic review by Aupérin et al that demonstrated prolonged overall 
survival with PCI for LD-SCLC.(192) Conversely, we found that PCI did not augment survival for ED-
SCLC, similar to a finding by Takahashi et al.(193) In their study people with ED-SCLC who had 
responded to chemotherapy were randomized to either; surveillance magnetic resonance imaging of 
the brain (3-monthly for 12 months then scans at 18 and 24 months after enrolment) or PCI. The 
study was terminated early as it was clear that PCI was not beneficial to survival. This finding, in 
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conjunction with our study, provides strong evidence that, for the most part, PCI in ED-SCLC has a 
limited role. 
Relevance to practice and guidelines 
The European Society of Medical Oncology SCLC clinical practice guideline was published in 2013 and 
therefore new data are not incorporated. However, Table 4 compares our conclusions with these 
recommendations and generally supports these. In particular, early thoracic radiotherapy and PCI for 
LD-SCLC and the cautious use of chemo-radiotherapy for people with worse PS. In contrast age, 
which is currently cited as a criterion for choosing cisplatin+etoposide, was not associated with 
poorer survival, especially in ED-SCLC. The European recommendations contain minimal information 
about appropriate patient selection and this can cause variation in chemotherapy administration, 
which is known to occur nationally.(194) Our study could reduce this variation as it quantifies 
survival so that better informed treatment decisions can be made. Similarly, it can assist with the 
appraisal of novel therapies as it is a comprehensive survival reference for current treatments.  
On the whole, recommended treatments for SCLC have remained unchanged for years when 
compared to NSCLC. This has reinforced the nihilistic connotations associated with SCLC. We have 
shown that survival has improved over time in SCLC; a finding which can raise optimism for the 
future. 
Future directions 
An updated version of the ESMO recommendations is expected to be published within the next year 
and will reflect some of the newer developments in SCLC, particularly immunotherapy and PCI for 
ED-SCLC. In addition to immunotherapy other classes of drugs such as RNA polymerase II inhibitors 
have shown promising results in phase II clinical trials and may become available for patients with 
relapsed SCLC in the future.(195) Similarly, clinical trials, such as the ADRIATIC trial (NCT03703297) 
are exploring whether combination immunotherapy can improve survival following concurrent 




We have conducted the largest systematic review and meta-analysis of survival in SCLC. Our findings 
support ESMO recommendations, in particular, early thoracic radiotherapy and PCI for LD-SCLC with 
the cautious use of chemotherapy for people with worse PS. Cisplatin and carboplatin are preferred, 
however, we found significant disparities in their long-term survival by ethnicity. This may relate to 
altered drug metabolism and the differing aetiological exposures for SCLC across ethnic groups. 
At present, early mortality risk is not included in the criteria for chemotherapy administration but it 
is a metric that can inform patient selection. Early mortality risk does not increase for the elderly and 
age should be cited cautiously as a selection factor. There is great optimism surrounding 
immunotherapy as it has the potential to revolutionise prognosis in SCLC. Importantly, our research 
sets a reference point for survival following current treatments to which the success of 
immunotherapies can be measured. 
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